December 5, 2017 / 4:03 PM / 8 months ago

BUZZ-Incyte Corp: Gains on positive initial data from study

** Biopharma company’s shares up 3 pct at $96.45

** Positive early-stage data in a collaborative study with Canadian biotech company Immunovaccine in patients with advanced ovarian cancer

** Initial data shows, for the first time, a significant number of tumor regressions in a combination therapy clinical trial - Frederic Ors, CEO of Immunovaccine

** INCY down ~4 pct this year, including session gains vs marginal gains in Nasdaq Biotech index (Reporting by Medha Singh in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below